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30 Myelodysplastic syndrome with isolated del (5q) and JAK2V617F mutation is a distinct entity within the World 
31 Health Organization (WHO) category myelodysplastic syndromes (MDS) [1] 
32 
33 
JAK2V617F is a gain of function mutation, typically associated with myeloproliferative neoplasms (MPN) [2]. 
35 However, approximately 5% of patients with isolated del (5q) also harbours the JAK2V617F mutation [3,4]. 
36 
37 No correlation was found between isolated del (5q) JAK2V617F mutated cases and clinical presentation, 
38 morphological features, disease transformation or patient outcome [4,5], although a few cases presented 
39 
with higher platelet and WBC count [3]. Lenalidomide was reported to be an effective treatment for the 
40 
41 
disease [6]. 
42 
43 We have recently studied a patient with del (5q) and JAK2V617F mutation transformed to acute 
44 myeloid leukaemia (AML) with complex karyotype and increased JAK2V617F mutation load. 
45 
46 
A 66 year old female presented with moderate anaemia and high platelet count (haemoglobin 100g/l, WBC 
48 7.2 x 10^9/l, platelets 800 x 10^9/l). Neutrophils were 4.95 x 10^9/l, eosinophils 0.21 x 10^9/l, monocytes 
49 0.14 x 10^9/l and lymphocytes 1.9 x 10^9/l. No blast cell was present in the peripheral blood. There was no 
50 spleno- or hepatomegaly. On marrow aspirate, only 8 metaphases showing a normal karyotype (46XX) 
51 could be analysed, due to the lack of growth of an adequate number of metaphases and the poor cellularity 
52 
of the sample. FISH analysis was limited to the study of 5q and demonstrated 5q31 deletion in 12% of the 
53 
54 nuclei. Thus, additional aberrations could not be identified. BCR/ABL rearrangements (p210, p190) were 
55 absent, while JAK2V617F mutation displayed an allele burden of 4.28%. 
56 
57 BM biopsy showed a 70% cellularity, slight dyserythropoiesis, moderate myeloid hyperplasia and marked 
58 proliferation of the megakaryocytic lineage with some dysplasia. A few megakaryocytes were large with 
59 
60 hyperlobulated nuclei; others were medium-sized, with round and/or hypolobulated nuclei. There were 3% 
61 CD34 positive blasts and moderate reticulin fibrosis (WHO MF-2). (Fig.1 a,b,c,e). A strong nuclear p53 
59 
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50 
immunostaining was detected in 2% hematopoietic cells (Fig.1 d). We proposed a diagnosis of MDS with del 
1 (5q) and JAK2V617F mutation. 
2 
3 The patient did not receive any therapy. No organomegaly nor leukoerythroblastosis was reported during 
4 
the course of the disease. Twenty-seven months later, she was admitted to the hospital 
6 because of persistent fever, severe anaemia and neutropenia (Hb level 7.5 g/l, WBC 2.3x10^9/l, 
7 neutrophils 0.75x10^9/l, platelets 137x10^9/l). There were 5% blast cells in the peripheral blood. 
8 
9 Chromosome banding analysis showed: 46,XX [1] / 45,XX, -7, del(5)(q13q33), del(13)(q14q34) [7] / 45, 
10 idem, del(2)(p12) [2]. FISH analysis demonstrated -7, del(5)(q31), del(13)(q14) (80%) without BCR/ABL, 
11 
AML1/ETO, PML/RARA, inv(16), MLL(11q23) translocation and +8. Molecular analysis didn’t identify FLT3 
13 (ITD, D835), NPM1 (exon 12) or MLL-PTD mutations. RQ-PCR (real-time quantitative polymerase chain 
14 reaction) detected 4,164 WT1 copies/10^4 ABL copies and 55.6% JAK2V617F mutation load. p53 sequencing 
15 analysis of exons 2-11 showed a c.742C>T, p.R248W mutation in exon 7, that is considered a missense 
16 deleterious mutation. 
17 
18 
19 BM demonstrated marked dyserythro-, dysgranulo- and dysmegakaryopoiesis, diffuse reticulin fibrosis and 
20 excess (25%) of CD34, CD117, CD33 and MPO positive blasts. (Fig.1 f,g,h,i,l). Strong nuclear p53 
21 immunostaining was found in more than 20% of hematopoietic cells, including some blasts (Fig.1 m). 
22 
23 
A diagnosis of AML with myelodysplasia-related changes was established. Induction therapy with 
24 
25 fludarabine, cytarabine and idarubicin failed; reinduction therapy with clofarabine and cytarabine was then 
26 performed. However, the disease still persisted in a control BM biopsy performed three months later. 
27 
28 Contrary to previous reports [4,5], our case of del (5q) with JAK2V617F mutation transformed to 
29 AML. MDS with isolated del(5q) has a very long median survival (145 months) and a low rate of 
30 
transformation (<10%) to AML [1]. On the contrary, our case transformed to AML in 27 months only: it is 
32 possible that the simultaneous presence of del (5q), JAK2V617F mutation and expression of p53 
33 accelerated leukemic transformation. Indeed, a strong p53 immunostaining in >1% of bone marrow 
34 progenitor cells is known to be significantly associated with higher acute myeloid leukemia risk [7]. 
35 The percentage of strongly p53 positive BM cells was 2% at the time of the initial biopsy but more than 20% 
36 
at the time of the leukemic transformation and included some blasts. Sequencing confirmed a p53 
37 
38 mutation. Therefore, it is possible that p53 mutation contributed to the unfavourable course of this case. 
39 
40 Moreover, the increase of JAK2V617F mutation load (10x of the initial value) can also explain the high number 
41 of large megakaryocytes with hyperlobulated or cloudy nuclei, typical of a MPN disease, that were 
42 appreciated in the BM biopsy performed at the time of the leukemic transformation. 
43 
44 
45 WHO recommends to classify patients with isolated del (5q) and JAK2V617F mutation in the MDS category 
46 rather than in the MDS/MPN category [1]. 
47 
48 However, the present case at diagnosis showed morphological features either of MDS and MPN. 
49 
Furthermore, in the following transformation into AML, some morphological features of MPN were 
51 retained (large megakaryocytes with hyperlobulated or cloudy nuclei), together with myelodysplasia 
52 related changes (marked dyserythro-, dysgranulo- and dysmegakaryopoiesis). 
53 
54 Therefore, on the basis of the clinical and pathological features of the present case, we suggest that it 
55 
would be more appropriate to classify MDS with del (5q) and JAK2V617F mutation in the WHO 
56 
57 MDS/MPN category rather than in the MDS category. 
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All procedures followed were in accordance with the ethical standards of the local institutional responsible 
1 committee on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008. 
2 Informed consent was obtained from the patient for being included in the study. 
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a  Slight dyserythropoiesis, moderate myeloid hyperplasia and marked proliferation of the megakaryocytic 
1 lineage with some dysplasia (H&E). b Large megakaryocytes with hyperlobulated nuclei and medium-sized 
2 
megakaryocytes with round and/or hypolobulated nuclei (Dominici). c Moderate reticulin fibrosis (WHO 
4 MF-2) (Gomori). d Strong nuclear p53 immunostaining in a few hematopoietic cells. e Dyserythropoiesis is 
5 well shown by CD71 immunostaining. 
6 
7 
f Hypercellular marrow with marked dyserythro-, dysgranulo- and dysmegakaryopoiesis and numerous 
8 
9 blasts (H&E). g A few micromegakaryocytes and one large megakaryocyte with hyperlobulated nucleus 
10 (Dominici). h Diffuse reticulin fibrosis (Gomori). i CD34 immunopositive blasts. l CD117 immunopositive 
11 
blasts. m Strong nuclear p53 immunostaining in numerous hematopoietic cells, including some blasts. 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 
 
 
 
 
 
 
 
 
 
C 
 
 
 
 
 
 
 
A B D E 
 
 
 
 
 
 
 
G L 
 
 
 
 
 
 
 
F H I M 
